KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Cash (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Change in Cash for 16 consecutive years, with $166.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 224.03% year-over-year to $166.0 million, compared with a TTM value of $690.2 million through Dec 2025, up 348.83%, and an annual FY2025 reading of $690.2 million, up 348.83% over the prior year.
  • Change in Cash was $166.0 million for Q4 2025 at Alnylam Pharmaceuticals, down from $376.9 million in the prior quarter.
  • Across five years, Change in Cash topped out at $497.7 million in Q3 2022 and bottomed at -$285.9 million in Q1 2022.
  • Average Change in Cash over 5 years is $58.0 million, with a median of $47.5 million recorded in 2022.
  • The sharpest move saw Change in Cash tumbled 249268.18% in 2021, then skyrocketed 2084.58% in 2024.
  • Year by year, Change in Cash stood at -$274.3 million in 2021, then rose by 24.6% to -$206.8 million in 2022, then decreased by 6.52% to -$220.3 million in 2023, then skyrocketed by 39.25% to -$133.8 million in 2024, then surged by 224.03% to $166.0 million in 2025.
  • Business Quant data shows Change in Cash for ALNY at $166.0 million in Q4 2025, $376.9 million in Q3 2025, and $93.6 million in Q2 2025.